Verastem (VSTM) Non-Current Deffered Revenue (2011 - 2013)
Verastem (VSTM) posted quarterly Non-Current Deffered Revenue of $16000.0 for Q2 2013, down 71.93% year-over-year from $57000.0 in Q2 2012, and down 42.86% quarter-over-quarter from $28000.0 in Q1 2013.
Analysis
Verastem (VSTM) Non-Current Deffered Revenue (2011 - 2013) Analysis & Trends
Verastem's Non-Current Deffered Revenue history runs 3 years deep, the most recent figure standing at $16000.0 for Q2 2013.
- In Q2 2013, Non-Current Deffered Revenue fell 71.93% year-over-year to $16000.0; the TTM figure through Jun 2013 stood at $16000.0 (down 71.93% YoY), while the FY2012 annual figure was $38000.0, down 48.65% from the prior year.
- Non-Current Deffered Revenue for Q2 2013 stood at $16000.0, down from $28000.0 in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $74000.0 in Q4 2011, with the low at $16000.0 in Q2 2013.
- The 3-year median for Non-Current Deffered Revenue is $47000.0 (2012), against an average of $46571.4.
- The sharpest annual moves came in 2012 and 2013: Non-Current Deffered Revenue tumbled 48.65% in 2012, then tumbled 71.93% in 2013.
- Verastem's Non-Current Deffered Revenue stood at $74000.0 in 2011, then sank by 48.65% to $38000.0 in 2012, then plunged by 57.89% to $16000.0 in 2013.
- Business Quant data shows VSTM's Non-Current Deffered Revenue at $16000.0 in Q2 2013, $28000.0 in Q1 2013, and $38000.0 in Q4 2012.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 147.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Verastem | 814.94 Mn | 678.59 Mn | 36.32 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2013 | 16,000.00 |
| Mar 31, 2013 | 28,000.00 |
| Dec 31, 2012 | 38,000.00 |
| Sep 30, 2012 | 47,000.00 |
| Jun 30, 2012 | 57,000.00 |
| Mar 31, 2012 | 66,000.00 |
| Dec 31, 2011 | 74,000.00 |